Breast cancer is one of the most harmful types of cancer that have already targeted hundreds of individuals in the U.S., mostly women, but men are not free from it. Because it is so typical, it is common sense that researchers would have much more extensive data on the disease than they actually have and read full article.
The main reason because there isn’t that much extensive information that detects patterns among current individuals with breast cancer and past ones is that scientists lack a functional system that is able to store this type of data.
However, recent news are going to change this reality forever as Eric Lefkofsky announced that his project, Tempus, is ready to be used in laboratories to assist in developing new therapies and methods to treat cancer based on past infected patients.
But, how do they do that?
First, we have to understand Tempus as a massive search engine, like Google but specialized in searching specific information about patients.
While treating a patient with breast cancer, now physicians could use Tempus to detect patterns in previous hosts that have similar characteristics and understand more about what to expect from the advancement of the disease and what therapies worked while what were the ones that didn’t.
Eric Lefkofsky is the founder of many successful startups like Groupon and has dedicated his newest investments in developing the technology Tempus, which is based in Chicago.
The first and currently the only scientists that will use Tempus to treat breast cancer are the doctors of the University of Chicago. Eric made a partnership with the University and will be lending the software that will improve their efficiency while the University will produce the best professionals to treat the disease and learn more about Eric.
The positive results of the system might take a while to show up, but it will be a step forward in developing more intelligent ways to combat diseases in the future, said a doctor of Chicago University.
- OlufunmilayoOlopade, the professor of medicine and human genetics at the same university, stated that, although breast cancer is among the most common cases of cancer, the thousands of patients that have been diagnosed with the disease have information that is very hard to access and understand with a full picture without dedicated software to do so.
The CEO of Tempus, Eric Lefkofsky, has done tons of advancements for the world of medicine, but this investment in the area is something new to the entrepreneur. He was a former owner of a venture fund named Lightbank and co-founder of Uptake Technologies.
Even if Lefkofsky does not have knowledge in the area of medicine, he has tons of experience in developing technologies that offer solutions and Eric’s lacrosse camp.